In today’s briefing:
- SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan
- Clearbridge Small Cap Growth Strategy Portfolio Manager Commentary Q1 2022
- Clearbridge Small Cap Strategy Portfolio Manager Commentary Q1 2022
SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan
- SanBio Co Ltd (4592 JP) is expected to receive approval for its first regenerative cell medicine SB623 for treating chronic motor deficit from traumatic brain injury in Japan this year.
- SB623, with current and future indication approvals, is targeting a large patient population of more than 50 million in major pharmaceutical markets globally. The indications have large unmet need.
- SanBio has a pipeline of five other pre-clinical drug candidates, entailing visibility beyond SB623.
Clearbridge Small Cap Growth Strategy Portfolio Manager Commentary Q1 2022
- Small cap growth stocks entered bear market territory during the quarter, buffeted by the prospects of monetary tightening, spiking inflation and the uncertainties wrought by Russia’s invasion of Ukraine.
Clearbridge Small Cap Strategy Portfolio Manager Commentary Q1 2022
- Small cap stocks had a rough ride during the first quarter, as increases in market volatility and investor uncertainty from major macro catalysts weighed on performance.
- The process of ending a decade of cheap and available capital has begun, creating headwinds that pose a challenge for the market as a whole.
Before it’s here, it’s on Smartkarma
